[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627328":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":46,"collaborators":21,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":21,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":78,"whyStopped":21,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Southern California","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pharmacist-Led Vascular Risk Factor Management","EXPERIMENTAL","Participants receive pharmacist-led management of hypertension and hypercholesterolemia using angiotensin receptor blockers and hydrophilic statins (or non-statin alternatives) over six months.",[13,14],"Drug: Angiotensin Receptor Blockers (ARBs)","Drug: Hydrophilic Statins or Non-Statin Alternative",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Angiotensin Receptor Blockers (ARBs)","Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes blood pressure management with angiotensin receptor blockers (ARBs).",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Hydrophilic Statins or Non-Statin Alternative","Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes cholesterol management with hydrophilic statins or a non-statin alternative if statins are not appropriate.",[9],[27],{"name":28,"role":29,"phone":30,"phoneExt":21,"email":31},"Hussein Yassine, MD","CONTACT","(323) 442-0272","hyassine@usc.edu",[33],{"facility":34,"status":21,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":21},"Clinical Sciences Building (CSC)","Los Angeles","California","90033","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-118.24368,34.05223,{"lat":44,"lon":43},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Hussein Yassine","Professor of Neurology and Department of Physiology and Neuroscience; Kenneth and Bette Volk Professorship in Neurology; Director, Center for Personalized Brain Health","100627328","phase-2-vascular-intervention-strategies-trial-for-alzheimers-100627328",false,"NCT07447206","Vascular Intervention Strategies Trial for Alzheimer's","Vascular Intervention Strategies Trial for Alzheimer's (VISTA)","VISTA","Inclusion Criteria:\n\n* APOE ε4 carrier (homozygote or heterozygote)\n* LDL-C of 100-250 mg\u002FdL\n* Systolic blood Pressure (SBP) 130-180 mm Hg\n* Age 50-75 years\n* Fluency in English\n* No dementia based on medical record review\n* Male or post-menopausal female\n\nExclusion Criteria:\n\n* One minute standing SBP \\\u003C 110 mm Hg\n* Arm circumference prevents from accurate BP measurement with use of available devices\n* Lost weight of \\> 10% unintendedly (within the past 6 months),\n* Contraindications to blood pressure and cholesterol lowering medications\n* Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)\n* Evidence of dementia based on medical record review\n* Living in a skilled nursing or rehabilitation facility\n* Receiving palliative or hospice care\n* Bipolar illness or schizophrenia\n* Drug or alcohol disorder\n* Receiving chronic opioid therapy\n* Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)\n* Severe loss of visual, hearing or communication ability\n* Organ transplant\n* History of stroke, symptomatic HF or left ventricular ejection fraction \\\u003C 35%\n* ESRD or eGFR \\\u003C 20 ml\u002Fmin \u002F1.73m2\n* Does not consent to be contacted or to have their medical record reviewed for research purposes\n* Concurrent participation in another clinical trial","ALL","50 Years","75 Years",{"count":62,"type":63},10,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.",[69,70,71],"Hypertension","Hypercholesterolemia","Dementia Risk Factors",[73,74,69,70,75,76,77],"APOE ε4 carriers","Dementia risk","Vascular risk factors","Pharmacist-led intervention","Feasibility study","NOT_YET_RECRUITING","2026-04-27",{"date":81,"type":82},"2026-05-04","ACTUAL",{"date":84,"type":63},"2026-05",{"date":86,"type":63},"2028-06",{"name":5,"class":6},1]